Critical Illness, Brain Dysfunction and Survivorship Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee.
JAMA Netw Open. 2023 Feb 1;6(2):e230380. doi: 10.1001/jamanetworkopen.2023.0380.
Sepsis is associated with long-term cognitive impairment and worse psychological and functional outcomes. Potential mechanisms include intracerebral oxidative stress and inflammation, yet little is known about the effects of early antioxidant and anti-inflammatory therapy on cognitive, psychological, and functional outcomes in sepsis survivors.
To describe observed differences in long-term cognitive, psychological, and functional outcomes of vitamin C, thiamine, and hydrocortisone between the intervention and control groups in the Vitamin C, Thiamine, and Steroids in Sepsis (VICTAS) randomized clinical trial.
DESIGN, SETTING, AND PARTICIPANTS: This prespecified secondary analysis reports the 6-month outcomes of the multicenter, double-blind, placebo-controlled VICTAS randomized clinical trial, which was conducted between August 2018 and July 2019. Adult patients with sepsis-induced respiratory and/or cardiovascular dysfunction who survived to discharge or day 30 were recruited from 43 intensive care units in the US. Participants were randomized 1:1 to either the intervention or control group. Cognitive, psychological, and functional outcomes at 6 months after randomization were assessed via telephone through January 2020. Data analyses were conducted between February 2021 and December 2022.
The intervention group received intravenous vitamin C (1.5 g), thiamine hydrochloride (100 mg), and hydrocortisone sodium succinate (50 mg) every 6 hours for 96 hours or until death or intensive care unit discharge. The control group received matching placebo.
Cognitive performance, risk of posttraumatic stress disorder and depression, and functional status were assessed using a battery of standardized instruments that were administered during a 1-hour telephone call 6 months after randomization.
After exclusions, withdrawals, and deaths, the final sample included 213 participants (median [IQR] age, 57 [47-67] years; 112 males [52.6%]) who underwent long-term outcomes assessment and had been randomized to either the intervention group (n = 108) or control group (n = 105). The intervention group had lower immediate memory scores (adjusted OR [aOR], 0.49; 95% CI, 0.26-0.89), higher odds of posttraumatic stress disorder (aOR, 3.51; 95% CI, 1.18-10.40), and lower odds of receiving mental health care (aOR, 0.38; 95% CI, 0.16-0.89). No other statistically significant differences in cognitive, psychological, and functional outcomes were found between the 2 groups.
In survivors of sepsis, treatment with vitamin C, thiamine, and hydrocortisone did not improve or had worse cognitive, psychological, and functional outcomes at 6 months compared with patients who received placebo. These findings challenge the hypothesis that antioxidant and anti-inflammatory therapy during critical illness mitigates the development of long-term cognitive, psychological, and functional impairment in sepsis survivors.
ClinicalTrials.gov Identifier: NCT03509350.
败血症与长期认知障碍以及更差的心理和功能结局有关。潜在机制包括颅内氧化应激和炎症,但对于早期抗氧化和抗炎治疗对败血症幸存者的认知、心理和功能结局的影响知之甚少。
描述维生素 C、硫胺素和氢化可的松在败血症中的维生素 C、硫胺素和类固醇(VICTAS)随机临床试验中,干预组与对照组之间长期认知、心理和功能结局的差异。
设计、地点和参与者:这是一项预设的二次分析,报告了多中心、双盲、安慰剂对照的 VICTAS 随机临床试验的 6 个月结局,该试验于 2018 年 8 月至 2019 年 7 月进行。从美国 43 个重症监护病房招募了因败血症引起的呼吸和/或心血管功能障碍而存活至出院或第 30 天的成年患者。参与者以 1:1 的比例随机分为干预组或对照组。通过电话在随机分组后 6 个月评估认知、心理和功能结局,通过电话进行了 1 小时的评估。数据分析于 2021 年 2 月至 2022 年 12 月进行。
干预组每 6 小时接受静脉注射维生素 C(1.5 g)、盐酸硫胺素(100 mg)和琥珀酸氢化可的松(50 mg),持续 96 小时,直至死亡或离开重症监护病房。对照组接受匹配的安慰剂。
使用一系列标准化仪器评估认知表现、创伤后应激障碍和抑郁的风险以及功能状态,这些仪器在随机分组后 6 个月的 1 小时电话中进行了评估。
排除退出和死亡后,最终样本包括 213 名参与者(中位数[IQR]年龄,57 [47-67] 岁;男性 112 名[52.6%]),他们接受了长期结局评估,并被随机分为干预组(n=108)或对照组(n=105)。干预组即时记忆评分较低(调整后的比值比[OR],0.49;95%CI,0.26-0.89),创伤后应激障碍的可能性更高(OR,3.51;95%CI,1.18-10.40),获得心理健康护理的可能性更低(OR,0.38;95%CI,0.16-0.89)。两组在认知、心理和功能结局方面没有其他统计学上显著差异。
在败血症幸存者中,与接受安慰剂的患者相比,用维生素 C、硫胺素和氢化可的松治疗并没有改善或出现更差的认知、心理和功能结局。这些发现挑战了这样一种假设,即在危重病期间使用抗氧化剂和抗炎剂可以减轻败血症幸存者长期认知、心理和功能障碍的发展。
ClinicalTrials.gov 标识符:NCT03509350。